News

Balloon pulmonary angioplasty benefits CTEPH patients: Study

Balloon pulmonary angioplasty (BPA) led to significant clinical improvements for people with chronic thromboembolic pulmonary hypertension (CTEPH) when used as an initial therapy or after a pulmonary endarterectomy (PEA) surgery, according to a global observational study. “Our data are in line with previous reports on changes of clinical and…

Outcomes after lung transplant similar in PH groups 2 and 3

The rates of long-term survival and perioperative complications after a lung transplant in people with group 2 or group 3 pulmonary hypertension (PH) aren’t significantly different from those in people who don’t have PH, a study reports. “No significant differences [between group 2 PH, group 3 PH, or no…

Study suggests BMPER protein as treatment target in PAH

Providing a protein called BMPER that is found at low levels in models of pulmonary arterial hypertension (PAH) may ease disease progression, a study suggests. “Our study identifies BMPER as a novel therapeutic target for pulmonary arterial hypertension and provides new insights into the underlying mechanisms of the disease,” researchers wrote.

Combination therapy effective in PAH with heart disease risk factors

People with pulmonary arterial hypertension (PAH) with at least one coexisting condition associated with cardiovascular disease had similar rates of hospitalization and mortality as those without these conditions after a combination treatment of macitentan and tadalafil, according to a real-world analysis. There was, however, a tendency towards more adverse…

Liquidia gets $50M more after first sale of Yutrepia to treat PH

Following the first commercial sale of Yutrepia (treprostinil) inhalation powder to treat certain types of pulmonary hypertension, the therapy’s maker, Liquidia, has received an additional $50 million under its financing agreement with Healthcare Royalty (HCRx). Per that HCR Agreement, Liquidia has been raising funds by selling HCRx…

Winrevair cuts clinical worsening risk with recent PAH diagnosis

Adding Winrevair (sotatercept-csrk) to background treatment significantly reduces the risk of clinical worsening in people with a recent pulmonary arterial hypertension (PAH) diagnosis, according to results from a Phase 3 clinical trial. The therapy led to “a statistically significant and clinically meaningful reduction in the risk of clinical…

Trial results for PAH treatment seralutinib expected early 2026

Enrollment is now complete — with nearly 400 participants with pulmonary arterial hypertension (PAH) — in the Phase 3 PROSERA clinical trial that’s testing the PAH treatment candidate seralutinib against a placebo in adults. Top-line results from PROSERA are expected in February 2026, according to Gossamer Bio, which is…

Beyond Air seeks FDA OK for new LungFit PH 2 NO device

Beyond Air has submitted a supplement application to the U.S. Food and Drug Administration (FDA) for its LungFit PH 2, a second-generation device for administering nitric oxide (NO) to treat persistent pulmonary hypertension of the newborn (PPHN). LungFit PH 2 is a smaller, lightweight, transport-ready version of the…

TPIP may improve circulation, exercise capacity in PAH: Study

A Phase 2b clinical trial of Insmed’s treprostinil palmitil inhalation powder (TPIP) suggested daily doses of the inhaled dry powder are well tolerated and may improve blood flow and exercise capacity in adults with pulmonary arterial hypertension (PAH). “The statistically significant and clinically meaningful results shown with TPIP…